HERNEXEOS Secures China Approval for Untreated HER2-Mutant NSCLC

China’s National Medical Products Administration (NMPA) has granted conditional approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib) as a first‑line monotherapy for adults with unresectable, locally advanced, or metastatic non‑small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) tyrosine kinase domain mutations.

The decision expands the oral HER2‑targeted therapy beyond its prior authorization in previously treated HER2‑mutant NSCLC. Full approval will depend on confirmatory evidence from the ongoing Phase III Beamion LUNG‑2 trial.

Clinical Evidence Driving the Decision

The conditional approval was supported by treatment‑naïve patient data from the Phase Ib Beamion LUNG‑1 study (NCT04886804). Among 74 evaluable patients, zongertinib achieved an objective response rate (ORR) of 75.7%, including complete responses in 10.8% and partial responses in 64.9%. Median duration of response reached 15.2 months.

Results were presented at the European Lung Cancer Congress 2026 and simultaneously published in The New England Journal of Medicine.

Mechanistic Differentiation in HER2 Targeting

Zongertinib is an irreversible tyrosine kinase inhibitor designed to selectively target HER2 while sparing wild‑type EGFR, aiming to reduce off‑target toxicities common with broader HER‑family inhibition.

HER2 mutations drive approximately 4% of NSCLC cases, representing a biologically aggressive subset with historically limited targeted options. Most patients present with advanced disease, where long‑term survival remains poor despite recent advances in precision oncology.

Safety Profile Reinforcing Development

Safety findings from a pooled population of 177 HER2‑mutant NSCLC patients in Beamion LUNG‑1 showed a manageable tolerability profile. Treatment‑related adverse events were primarily low grade, with dose reductions in 9% and discontinuations in 6%.

Importantly, rates of interstitial lung disease (ILD) and diarrhea adverse events often associated with HER‑family TKIs were low, supporting continued development.

Expert Perspective on Clinical Need

Professor Yi‑Long Wu of Guangdong Provincial People’s Hospital and Chairman of the Chinese Thoracic Oncology Group emphasized that HER2‑mutant lung cancer patients have long faced diagnostic and therapeutic barriers, limiting access to precision treatment approaches.

Boehringer leadership stated the approval strengthens the company’s broader strategy in HER2‑driven cancers across multiple tumor types and disease stages.

Expanding Development Across Disease Stages

Boehringer Ingelheim continues to advance zongertinib in both earlier‑stage and advanced settings. The Phase III Beamion LUNG‑2 (NCT06151574) trial is evaluating the therapy in first‑line advanced HER2‑mutant NSCLC, while Beamion LUNG‑3 (NCT07195695) is testing adjuvant zongertinib in resectable Stage II–IIIB HER2‑mutant NSCLC. Beyond lung cancer, the company is also exploring HER2 inhibition in breast and gastric malignancies, underscoring its commitment to precision oncology and long‑term portfolio expansion.

Regulatory Milestone with Global Implications

This conditional approval positions zongertinib as the first HER2‑selective TKI authorized in China for front‑line NSCLC, marking a significant advance for patients with HER2‑mutant lung cancer. The therapy’s selective inhibition profile, strong response rates, and manageable safety signal a potential paradigm shift, pending Phase III confirmation.

Reference

China approves HERNEXEOS initial treatment lung cancer | Boehringer Ingelheim

Study Details | NCT04886804 | Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People with Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | ClinicalTrials.gov